000513 丽珠集团
交易中 10-23 13:06:18
资讯
新帖
简况
丽珠集团(000513)10月15日主力资金净买入701.36万元
证券之星 · 10-16
丽珠集团(000513)10月15日主力资金净买入701.36万元
【机构调研记录】华宝基金调研丽珠集团、源杰科技
证券之星 · 10-15
【机构调研记录】华宝基金调研丽珠集团、源杰科技
丽珠集团:未来几年制剂国际化的收入增长主要来自产品完成海外注册后形成的销售收入等
南方财经网 · 10-14
丽珠集团:未来几年制剂国际化的收入增长主要来自产品完成海外注册后形成的销售收入等
丽珠集团:莱康奇塔单抗未来将在国内依托公司特药销售团队自主开展商业化
南方财经网 · 10-14
丽珠集团:莱康奇塔单抗未来将在国内依托公司特药销售团队自主开展商业化
丽珠集团:预计全年收入端降幅与上半年基本持平,利润端降幅将较上半年收窄
南方财经网 · 10-14
丽珠集团:预计全年收入端降幅与上半年基本持平,利润端降幅将较上半年收窄
丽珠集团(000513)10月13日主力资金净卖出4587.88万元
证券之星 · 10-14
丽珠集团(000513)10月13日主力资金净卖出4587.88万元
丽珠集团(000513)披露为子公司提供担保的进展公告,10月12日股价下跌0.13%
证券之星 · 10-12
丽珠集团(000513)披露为子公司提供担保的进展公告,10月12日股价下跌0.13%
股市必读:丽珠集团新发布《H股公告:证券变动月报表》
证券之星 · 10-12
股市必读:丽珠集团新发布《H股公告:证券变动月报表》
丽珠集团为3家全资子公司提供担保 实际担保余额190,665.59万元
同花顺 · 10-09
丽珠集团为3家全资子公司提供担保 实际担保余额190,665.59万元
丽珠集团(000513)10月8日主力资金净卖出1.43亿元
证券之星 · 10-09
丽珠集团(000513)10月8日主力资金净卖出1.43亿元
10月8日丽珠集团(000513)龙虎榜数据:机构净卖出1031.59万元,北向资金净卖出161.24万元
证券之星 · 10-08
10月8日丽珠集团(000513)龙虎榜数据:机构净卖出1031.59万元,北向资金净卖出161.24万元
异动快报:丽珠集团(000513)10月8日13点28分触及跌停板
证券之星 · 10-08
异动快报:丽珠集团(000513)10月8日13点28分触及跌停板
丽珠集团连续3个交易日收盘价格涨幅偏离值累计达20.82%
财中社 · 09-29
丽珠集团连续3个交易日收盘价格涨幅偏离值累计达20.82%
丽珠集团最新公告:子公司注射用醋酸亮丙瑞林微球11.25mg获批上市
证券之星 · 09-29
丽珠集团最新公告:子公司注射用醋酸亮丙瑞林微球11.25mg获批上市
丽珠集团成交额创2025年7月24日以来新高
同花顺 · 09-29
丽珠集团成交额创2025年7月24日以来新高
9月28日丽珠集团(000513)龙虎榜数据:北向资金净买入4307.39万元
证券之星 · 09-28
9月28日丽珠集团(000513)龙虎榜数据:北向资金净买入4307.39万元
9月28日丽珠集团涨10.01%,疫苗ETF国泰基金重仓该股
证券之星 · 09-28
9月28日丽珠集团涨10.01%,疫苗ETF国泰基金重仓该股
丽珠集团涨10.01%,东海证券一周前给出“买入”评级
证券之星 · 09-28
丽珠集团涨10.01%,东海证券一周前给出“买入”评级
医药韧性凸显!药ETF华宝(562050)逆市飘红,丽珠集团涨停!医疗器械局部强势,迈瑞、联影携手走强
新浪基金 · 09-28
医药韧性凸显!药ETF华宝(562050)逆市飘红,丽珠集团涨停!医疗器械局部强势,迈瑞、联影携手走强
生物疫苗概念走高 丽珠集团涨停
南方财经网 · 09-28
生物疫苗概念走高 丽珠集团涨停
加载更多
公司概况
公司名称:
丽珠医药集团股份有限公司
所属行业:
医药制造业
上市日期:
1993-10-28
主营业务:
丽珠医药集团股份有限公司的主营业务是医药产品的研发、生产及销售。公司的主要产品是化学制剂产品、原料药和中间体、中药制剂、生物制品、诊断试剂及设备。公司国内领先的产业体系完备、研产销一体化程度高的大型综合型医药企业集团,长期荣登“中国化学制药行业工业企业综合实力百强”“中国化药企业百强”等权威榜单,先后获评国家高新技术企业、国家技术创新示范企业及国家企业技术中心。
发行价格:
6.38
{"stockData":{"symbol":"000513","market":"SZ","secType":"STK","nameCN":"丽珠集团","latestPrice":26.12,"timestamp":1792731978000,"preClose":26.02,"halted":0,"volume":5648200,"delay":0,"changeRate":0.0038,"floatShares":568000000,"shares":888000000,"eps":1.8858,"marketStatus":"交易中","change":0.1,"latestTime":"10-23 13:06:18","open":25.81,"high":26.12,"low":25.7,"amount":146000000,"amplitude":0.0161,"askPrice":26.12,"askSize":40,"bidPrice":26.1,"bidSize":59,"shortable":0,"etf":0,"ttmEps":1.8858,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1792738800000},"marketStatusCode":2,"adr":0,"adjPreClose":26.02,"symbolType":"stock","openAndCloseTimeList":[[1792719000000,1792726200000],[1792731600000,1792738800000]],"highLimit":28.62,"lowLimit":23.42,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":887907171,"isCdr":false,"pbRate":1.73,"roa":"--","peRate":13.850886,"roe":"6.64%","epsLYR":2.27,"committee":0.250909,"marketValue":23192000000,"turnoverRate":0.01,"status":0,"hkstockBrief":{"symbol":"01513","market":"HK","secType":"STK","nameCN":"丽珠医药","latestPrice":20.54,"timestamp":1792731913147,"preClose":20.4,"halted":0,"volume":286700,"delay":0,"premium":"-33.08"},"floatMarketCap":14827000000},"requestUrl":"/m/hq/s/000513","defaultTab":"news","newsList":[{"id":"2675512825","title":"丽珠集团(000513)10月15日主力资金净买入701.36万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675512825","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675512825?lang=zh_cn&edition=full","pubTime":"2026-10-16 09:07","pubTimestamp":1792112828,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月15日收盘,丽珠集团报收于28.03元,上涨0.07%,换手率2.15%,成交量12.23万手,成交额3.46亿元。近5日资金流向一览见下表:丽珠集团融资融券信息显示,融资方面,当日融资买入2377.46万元,融资偿还3860.29万元,融资净偿还1482.83万元。丽珠集团主营业务:以医药产品的研发、生产及销售为主业,产品涵盖制剂产品、原料药和中间体及诊断试剂及设备,覆盖了消化道、辅助生殖、精神及肿瘤免疫等众多治疗领域。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600008734.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","000513","BK0239","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675000373","title":"【机构调研记录】华宝基金调研丽珠集团、源杰科技","url":"https://stock-news.laohu8.com/highlight/detail?id=2675000373","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675000373?lang=zh_cn&edition=full","pubTime":"2026-10-15 08:11","pubTimestamp":1792023106,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及10月14日披露的机构调研信息,华宝基金近期对2家上市公司进行了调研,相关名单如下:1)丽珠集团 调研纪要:2026年公司经营阶段性承压,主要受成熟产品医保谈判及集采降价影响,预计全年收入降幅与上半年基本持平,利润降幅收窄。2)源杰科技 调研纪要:公司第三季度利润增长主要驱动力来自产能释放,在旺盛市场需求下,业绩实现环比增长,预计2026年第四季度及2027年将继续保持增长态势。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101500006674.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","SGXZ81163826.USD","SGXZ49509284.SGD","BK0028","000513","BK0188","BK0187","688498","BK0214"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675994323","title":"丽珠集团:未来几年制剂国际化的收入增长主要来自产品完成海外注册后形成的销售收入等","url":"https://stock-news.laohu8.com/highlight/detail?id=2675994323","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675994323?lang=zh_cn&edition=full","pubTime":"2026-10-14 09:18","pubTimestamp":1791940739,"startTime":"0","endTime":"0","summary":"南财智讯10月14日电,丽珠集团在投资者关系活动中表示,公司制剂国际化并非简单地将产品一次性授权给当地合作方,而是希望逐步提升重点区域的本地化运营能力。在主要区域,公司会选择重点国家,通过自建团队、收购当地企业或整合本地生产及渠道平台建立区域支点,并在此基础上与当地合作伙伴共同推进周边国家的产品注册、授权和销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610143895006736.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610143895006736.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK0028","000513","BK0188","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675399451","title":"丽珠集团:莱康奇塔单抗未来将在国内依托公司特药销售团队自主开展商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2675399451","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675399451?lang=zh_cn&edition=full","pubTime":"2026-10-14 09:18","pubTimestamp":1791940680,"startTime":"0","endTime":"0","summary":"南财智讯10月14日电,丽珠集团在投资者关系活动中表示,莱康奇塔单抗是公司未来数年的重点产品之一。公司自2025年起已启动该产品的商业化准备工作,未来将在国内依托公司特药销售团队自主开展商业化。商业化方面,公司计划通过核心专家及临床证据驱动的学术推广,覆盖现有治疗不足、产生耐药或需要更高皮损清除率的患者,同时关注基层市场生物制剂渗透率提升的机会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610143895009524.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610143895009524.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["000513","BK0028","BK0239","BK0187","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675139944","title":"丽珠集团:预计全年收入端降幅与上半年基本持平,利润端降幅将较上半年收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=2675139944","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675139944?lang=zh_cn&edition=full","pubTime":"2026-10-14 09:14","pubTimestamp":1791940440,"startTime":"0","endTime":"0","summary":"南财智讯10月14日电,丽珠集团在投资者关系活动中表示,2026年公司经营阶段性承压,主要受到部分成熟产品医保谈判及集采降价集中执行的影响。随着相关影响逐步消化,公司将继续推进新品准入和商业化、制剂国际化及经营效率提升,努力改善经营表现。预计全年收入端降幅与上半年基本持平,利润端降幅将较上半年收窄、同比表现向收入端靠拢。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610143894993632.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610143894993632.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["000513","BK0239","BK0028","BK0187","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675939951","title":"丽珠集团(000513)10月13日主力资金净卖出4587.88万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675939951","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675939951?lang=zh_cn&edition=full","pubTime":"2026-10-14 09:11","pubTimestamp":1791940308,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月13日收盘,丽珠集团报收于29.43元,下跌3.38%,换手率3.15%,成交量17.89万手,成交额5.31亿元。近5日资金流向一览见下表:丽珠集团融资融券信息显示,融资方面,当日融资买入3850.96万元,融资偿还6867.43万元,融资净偿还3016.47万元。丽珠集团主营业务:以医药产品的研发、生产及销售为主业,产品涵盖制剂产品、原料药和中间体及诊断试剂及设备,覆盖了消化道、辅助生殖、精神及肿瘤免疫等众多治疗领域。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400008284.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0188","BK0187","000513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674587634","title":"丽珠集团(000513)披露为子公司提供担保的进展公告,10月12日股价下跌0.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2674587634","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674587634?lang=zh_cn&edition=full","pubTime":"2026-10-12 17:47","pubTimestamp":1791798437,"startTime":"0","endTime":"0","summary":"近日,丽珠医药集团股份有限公司披露《关于为子公司提供担保的进展公告》。公告显示,公司于2026年9月为子公司丽珠制药厂、珠海医贸及丽珠合成分别与中国民生银行、交通银行签署担保合同,合计新增担保金额60,000.00万元。其中为丽珠制药厂、珠海医贸各提供20,000.00万元最高额保证担保,为丽珠合成提供合计40,000.00万元担保。截至2026年9月30日,公司实际对外担保余额为190,665.59万元,占归属于母公司净资产的13.73%,均为对子公司的担保。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200023930.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0188","BK0187","000513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674284348","title":"股市必读:丽珠集团新发布《H股公告:证券变动月报表》","url":"https://stock-news.laohu8.com/highlight/detail?id=2674284348","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674284348?lang=zh_cn&edition=full","pubTime":"2026-10-12 01:02","pubTimestamp":1791738133,"startTime":"0","endTime":"0","summary":"公司公告汇总:截至2026年9月30日,H股与A股股本结构无变动,公众持股量符合港交所规则要求。公司公告汇总H股公告:证券变动月报表截至2026年9月30日,丽珠医药集团H股与A股的法定/注册股本、已发行股份及库存股份数目均无变动;H股与A股上月底结存与本月底结存数量一致;H股类别持续满足香港上市规则规定的公众持股量要求;本月无股份发行、购回或出售事项。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200000334.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","161027","000513","BK0239","BK0188","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674657859","title":"丽珠集团为3家全资子公司提供担保 实际担保余额190,665.59万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674657859","media":"同花顺","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674657859?lang=zh_cn&edition=full","pubTime":"2026-10-09 19:32","pubTimestamp":1791545520,"startTime":"0","endTime":"0","summary":"10月9日,丽珠医药(01513.HK)2026年9月分别与中国民生银行股份有限公司珠海分行及交通银行股份有限公司珠海分行签署担保合同,为3家全资子公司提供连带责任保证担保,担保主债权本金最高额 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261009/c680537970.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261009/c680537970.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK0239","BK0028","000513","BK0187","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674881973","title":"丽珠集团(000513)10月8日主力资金净卖出1.43亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674881973","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674881973?lang=zh_cn&edition=full","pubTime":"2026-10-09 09:11","pubTimestamp":1791508263,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月8日收盘,丽珠集团报收于29.61元,下跌10.0%,跌停,换手率6.15%,成交量34.91万手,成交额10.65亿元。近5日资金流向一览见下表:丽珠集团融资融券信息显示,融资方面,当日融资买入9310.58万元,融资偿还6438.08万元,融资净买入2872.5万元。丽珠集团主营业务:以医药产品的研发、生产及销售为主业,产品涵盖制剂产品、原料药和中间体及诊断试剂及设备,覆盖了消化道、辅助生殖、精神及肿瘤免疫等众多治疗领域。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900007128.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","000513","BK0187","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673388073","title":"10月8日丽珠集团(000513)龙虎榜数据:机构净卖出1031.59万元,北向资金净卖出161.24万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2673388073","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673388073?lang=zh_cn&edition=full","pubTime":"2026-10-08 17:41","pubTimestamp":1791452516,"startTime":"0","endTime":"0","summary":"证券之星消息,沪深交易所2026年10月8日公布的交易公开信息显示,丽珠集团因日跌幅偏离值达到7%的前5只证券登上龙虎榜。此次是近5个交易日内第3次上榜。截至2026年10月8日收盘,丽珠集团报收于29.61元,下跌10.0%,跌停,换手率6.15%,成交量34.91万手,成交额10.65亿元。从龙虎榜公布的当日买卖数据来看,机构合计净卖出1031.59万元,北向资金合计净卖出161.24万元。深股通专用、沪股通专用为北向资金的交易席位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800023198.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0187","BK0239","000513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673000028","title":"异动快报:丽珠集团(000513)10月8日13点28分触及跌停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2673000028","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673000028?lang=zh_cn&edition=full","pubTime":"2026-10-08 13:30","pubTimestamp":1791437449,"startTime":"0","endTime":"0","summary":"证券之星10月8日盘中消息,13点28分丽珠集团(000513)触及跌停板。其所属行业化学制药目前下跌。领涨股为海辰药业。该股为新冠病毒防治,中药,优化生育(三孩)概念热股。9月30日的资金流向数据方面,主力资金净流出8718.08万元,占总成交额5.79%,游资资金净流入941.0万元,占总成交额0.62%,散户资金净流入7777.08万元,占总成交额5.16%。近5日资金流向一览见下表:丽珠集团主要指标及行业内排名如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800013505.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000513","BK0188","BK0187","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671215272","title":"丽珠集团连续3个交易日收盘价格涨幅偏离值累计达20.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671215272","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671215272?lang=zh_cn&edition=full","pubTime":"2026-09-29 18:44","pubTimestamp":1790678640,"startTime":"0","endTime":"0","summary":"9月29日,丽珠集团(000513/01513)发布公告,公司股票在9月24日、28日及29日连续3个交易日,收盘价格涨幅偏离值累计达到20.82%。2026年中期,丽珠集团实现收入50.00亿元,归母净利润9.32亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609293886583521.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609293886583521.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["000513","BK0028","BK0188","BK0187","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671189712","title":"丽珠集团最新公告:子公司注射用醋酸亮丙瑞林微球11.25mg获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2671189712","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671189712?lang=zh_cn&edition=full","pubTime":"2026-09-29 17:50","pubTimestamp":1790675423,"startTime":"0","endTime":"0","summary":"丽珠集团(000513.SZ)公告称,公司控股子公司上海丽珠制药收到国家药监局核准签发的《药品补充申请批准通知书》,注射用醋酸亮丙瑞林微球11.25mg(3个月剂型)获批上市。该药品为化学药品注射剂,用于绝经前乳腺癌、前列腺癌及中枢性性早熟。截至目前,该药品累计研发投入约9405.48万元。国内仅上海丽珠持有该剂型批文,2025年国内3个月长效GnRHa缓释制剂终端销售额占比27%。此次获批填补国内技术空白,实现公司该产品规格全覆盖。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900029685.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","000513","BK0187","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671262921","title":"丽珠集团成交额创2025年7月24日以来新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2671262921","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671262921?lang=zh_cn&edition=full","pubTime":"2026-09-29 10:29","pubTimestamp":1790648940,"startTime":"0","endTime":"0","summary":"数据宝统计,截至09:59,丽珠集团成交额10.33亿元,创2025年7月24日以来新高。最新股价上涨8.57%,换手率5.73%。上一交易日该股全天成交额为8.43亿元。据天眼查APP显示,丽珠医药集团股份有 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260929/c680349938.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260929/c680349938.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0028","BK0239","000513","BK0187","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670356202","title":"9月28日丽珠集团(000513)龙虎榜数据:北向资金净买入4307.39万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2670356202","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670356202?lang=zh_cn&edition=full","pubTime":"2026-09-28 17:52","pubTimestamp":1790589170,"startTime":"0","endTime":"0","summary":"证券之星消息,沪深交易所2026年9月28日公布的交易公开信息显示,丽珠集团因日涨幅偏离值达到7%的前5只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年9月28日收盘,丽珠集团报收于30.34元,上涨10.01%,涨停,换手率4.92%,成交量27.94万手,成交额8.43亿元。从龙虎榜公布的当日买卖数据来看,北向资金合计净买入4307.39万元。深股通专用、沪股通专用为北向资金的交易席位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800023516.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000513","BK0188","BK0028","BK0187","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670828026","title":"9月28日丽珠集团涨10.01%,疫苗ETF国泰基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2670828026","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670828026?lang=zh_cn&edition=full","pubTime":"2026-09-28 16:48","pubTimestamp":1790585321,"startTime":"0","endTime":"0","summary":"证券之星消息,9月28日丽珠集团涨10.01%,收盘报30.34元,换手率4.92%,成交量27.94万手,成交额8.43亿元。根据2026基金半年报公募基金重仓股数据,重仓该股的公募基金共7家,其中持有数量最多的公募基金为国泰基金的疫苗ETF国泰。疫苗ETF国泰目前规模为1.4亿元,最新净值0.5465,较上一交易日下跌2.39%,近一年下跌18.05%。疫苗ETF国泰的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800021642.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0188","BK0187","159643","000513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670828077","title":"丽珠集团涨10.01%,东海证券一周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2670828077","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670828077?lang=zh_cn&edition=full","pubTime":"2026-09-28 16:48","pubTimestamp":1790585312,"startTime":"0","endTime":"0","summary":"今日丽珠集团涨10.01%,收盘报30.34元。2026年9月18日,东海证券研究员杜永宏发布了对丽珠集团的研报《公司简评报告:业绩短期承压,新品放量可期》,该研报对丽珠集团给出“买入”评级。公司成熟品种有望逐渐企稳,新产品放量可期,维持“买入”评级。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为中金公司的宋歌。丽珠集团个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800021639.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","000513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670286537","title":"医药韧性凸显!药ETF华宝(562050)逆市飘红,丽珠集团涨停!医疗器械局部强势,迈瑞、联影携手走强","url":"https://stock-news.laohu8.com/highlight/detail?id=2670286537","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670286537?lang=zh_cn&edition=full","pubTime":"2026-09-28 13:11","pubTimestamp":1790572260,"startTime":"0","endTime":"0","summary":"制药板块顽强抗跌,场内唯一跟踪制药指数的药ETF华宝一度逆市飘红,创新药概念股丽珠集团涨停封板,健康元、康弘药业、普洛药业齐涨逾5%。把握超跌医药新机遇,投资工具关注:药ETF华宝:全市场唯一跟踪制药指数的ETF,“70%创新药+20%中药”独家配比,兼具创新药高成长及中药高股息。医疗ETF华宝:全市场医药医疗类ETF旗舰,Q2规模256.24亿元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-28/doc-initkarm3859610.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159883","MEDX","GDOC","159938","IEIH","PTH","BK0188","BK0239","LGHT","09939","BK1100","09996","BK1574","BK1583","BK0187","562050","BK1515","000513","MDEV","HART","AGNG","BK0028","BK1161","LNGR","RSPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670400427","title":"生物疫苗概念走高 丽珠集团涨停","url":"https://stock-news.laohu8.com/highlight/detail?id=2670400427","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670400427?lang=zh_cn&edition=full","pubTime":"2026-09-28 10:01","pubTimestamp":1790560860,"startTime":"0","endTime":"0","summary":"生物疫苗概念走高 丽珠集团涨停","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609283884832561.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609283884832561.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0187","BK0188","000513","BK0239","159657","BK0028"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1792731979862,"stockEarnings":[{"period":"1week","weight":-0.0717},{"period":"1month","weight":0.0076},{"period":"3month","weight":-0.1003},{"period":"6month","weight":-0.1396},{"period":"1year","weight":-0.2466},{"period":"ytd","weight":-0.181}],"compareEarnings":[{"period":"1week","weight":-0.0133},{"period":"1month","weight":-0.0744},{"period":"3month","weight":-0.0409},{"period":"6month","weight":-0.1034},{"period":"1year","weight":-0.0653},{"period":"ytd","weight":-0.0783}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"丽珠医药集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"59540人(较上一季度增加0.16%)","perCapita":"9533股","listingDate":"1993-10-28","address":"广东省珠海市金湾区创业北路38号总部大楼","registeredCapital":"88790万元","survey":" 丽珠医药集团股份有限公司的主营业务是医药产品的研发、生产及销售。公司的主要产品是化学制剂产品、原料药和中间体、中药制剂、生物制品、诊断试剂及设备。公司国内领先的产业体系完备、研产销一体化程度高的大型综合型医药企业集团,长期荣登“中国化学制药行业工业企业综合实力百强”“中国化药企业百强”等权威榜单,先后获评国家高新技术企业、国家技术创新示范企业及国家企业技术中心。","listedPrice":6.38},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"丽珠集团(000513)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供丽珠集团(000513)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"丽珠集团,000513,丽珠集团股票,丽珠集团股票老虎,丽珠集团股票老虎国际,丽珠集团行情,丽珠集团股票行情,丽珠集团股价,丽珠集团股市,丽珠集团股票价格,丽珠集团股票交易,丽珠集团股票购买,丽珠集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"丽珠集团(000513)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供丽珠集团(000513)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}